Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients with Aspirin Resistance

Launched by SIRIRAJ HOSPITAL · Dec 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of taking aspirin once a day compared to taking it twice a day for patients with high-risk myeloproliferative neoplasms (MPN) who may not respond well to aspirin, a condition known as aspirin resistance. The goal is to see if increasing the dose of aspirin can help prevent blood clots and improve the health of these patients. Participants will include adults at least 18 years old who have a specific type of MPN that does not involve a certain genetic marker.

If you decide to join the study, you will receive either the once daily or twice daily aspirin regimen, and your response to the treatment will be monitored over two years. This includes tests to check how well your platelets are functioning and keeping track of any blood clots or side effects you may experience. The study is currently recruiting participants and aims to provide valuable information about the best way to manage aspirin resistance in patients with MPN.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Philadelphia negative Myeloproliferative neoplasms aged at least 18 years old
• Exclusion Criteria:
• • Concomitant other active malignancy or cured less than 6 months
• • Platelet count less than 50,000/microL
• • Receiving anticoagulant
• • Active peptic ulcer
• • Active bleeding or Planning to undergo procedure/operation with bleeding risk
• • No laboratory aspirin resistance with LTA method